Senior Scientist Bioinformatics (m/f/d)

As a Senior Scientist Bioinformatics, you will lead the analysis and integration of transcriptomic and multi-omics data, including RNA-seq and spatial transcriptomics, from both clinical trial samples and public datasets. You will translate complex data into actionable biological insights, supporting biomarker discovery and patient stratification while collaborating closely with cross-functional teams to advance clinical development.

Your responsibilities include:

• Analyze and interpret complex transcriptomic and multi-omics datasets, including bulk and single-cell RNA-seq, spatial transcriptomics, proteomics, metabolomics, and ctDNA analysis
• Integrate data from diverse sources, including publicly available datasets (e.g., TCGA and GEO) and clinical trial samples, to generate biologically meaningful insights
• Develop, implement, and optimize computational pipelines for processing and analysis of high-throughput sequencing data
• Ensure high data quality through robust quality control, normalization, and reproducible analysis workflows
• Organize, manage, and maintain large-scale datasets in a structured and accessible manner
• Document analytical methods, workflows, and results to ensure transparency and reproducibility
• Provide scientific leadership for assigned research projects by proactively building structured research plans and driving execution in alignment with company strategy and translational objectives
• Translate research questions into clear analytical strategies and guide projects from data-driven hypothesis generation to actionable conclusions
• Stay current with advances in bioinformatics and emerging technologies, and apply innovative methods where appropriate
• Collaborate closely with scientists, clinicians, and cross-functional teams to interpret data and inform experimental design
• Communicate findings effectively through presentations, reports, and contributions to scientific publications
• Contribute to collaborative research projects that support biomarker discovery and clinical development

• Ph.D. in Bioinformatics, Computational Biology, Genomics, or a related field
• Proficient in programming languages such as Python, R, or similar
• Experienced with bioinformatics tools and workflows for bulk and single-cell RNA-seq and spatial transcriptomics analysis (e.g., STAR, HISAT2, DESeq2, Seurat, Scanpy, Squidpy)
• Hands-on experience with bulk and single-cell RNA-seq and spatial transcriptomics, including data visualization approaches; additional experience with proteomics, metabolomics, and ctDNA data is a plus
• Strong understanding of statistical methods for high-dimensional data analysis
• Proven ability to work with and derive insights from large-scale biological datasets
• Experience in immunology, preferably with a focus on tumor immunology, is considered an asset
• Experienced in interdisciplinary collaboration and contributing to scientific publications
• Strong problem-solving skills and critical thinking, with a structured and hypothesis-driven approach to research
• Ability to translate research questions into clear analytical strategies and guide projects from data generation to actionable conclusions
• Excellent communication skills, both written and verbal
• Able to manage multiple projects, prioritize effectively, and meet deadlines in a dynamic environment

• The opportunity to contribute to the advancement of a promising clinical-stage oncology program
• A role within a dynamic biotech company at the forefront of innovative cancer therapies
• A collaborative and supportive team environment with a strong sense of shared purpose
• Flexible working arrangements, including the option for partial remote work while maintaining regular on-site collaboration
• A secure, permanent employment contract
• A competitive compensation package and attractive employee benefits

CatalYm is a biotech company based in Martinsried near Munich, developing innovative immunotherapies to transform cancer patients’ lives by effectively engaging their own immune systems to combat this malignant disease. We are now advancing to Phase 2b studies to confirm visugromab, our lead antibody, that has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment. Our mission is to rapidly bring our next-generation immuno-oncology products to patients in need. Are you ready to board the fast-accelerating visugromab train in Martinsried? Then join us!